Evidence map›Paper›PMID 26075891›Full record

ArticlePloS one2015

Maintenance of Mouse Nephron Progenitor Cells in Aggregates with Gamma-Secretase Inhibitor.

Shunsuke Yuri, Masaki Nishikawa, Naomi Yanagawa, Oak D Jo, Norimoto Yanagawa

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Shunsuke YuriMedical and Research Services, Greater Los Angeles Veterans Affairs Healthcare System at Sepulveda, North Hills, California, United States of America; University of California at Los Angeles, David Geffen School of Medicine, Los Angeles, California, United States of America.
Masaki NishikawaMedical and Research Services, Greater Los Angeles Veterans Affairs Healthcare System at Sepulveda, North Hills, California, United States of America; University of California at Los Angeles, David Geffen School of Medicine, Los Angeles, California, United States of America.
Naomi YanagawaMedical and Research Services, Greater Los Angeles Veterans Affairs Healthcare System at Sepulveda, North Hills, California, United States of America; University of California at Los Angeles, David Geffen School of Medicine, Los Angeles, California, United States of America.
Oak D JoMedical and Research Services, Greater Los Angeles Veterans Affairs Healthcare System at Sepulveda, North Hills, California, United States of America; University of California at Los Angeles, David Geffen School of Medicine, Los Angeles, California, United States of America.
Norimoto YanagawaMedical and Research Services, Greater Los Angeles Veterans Affairs Healthcare System at Sepulveda, North Hills, California, United States of America; University of California at Los Angeles, David Geffen School of Medicine, Los Angeles, California, United States of America.
University of California, Los Angeles · USVA Greater Los Angeles Healthcare System · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Knowledge on how to maintain and expand nephron progenitor cells (NPC) in vitro is important to provide a potentially valuable source for kidney replacement therapies. In our present study, we examined the possibility of optimizing NPC maintenance in the "re-aggregate" system. We found that Six2-expressing (Six2(+))-NPC could be maintained in aggregates reconstituted with dispersed cells from E12.5 mouse embryonic kidneys for at least up to 21 days in culture. The maintenance of Six2(+)-NPC required the presence of ureteric bud cells. The number of Six2(+)-NPC increased by more than 20-fold at day 21, but plateaued after day 14. In an attempt to further sustain NPC proliferation by passage subculture, we found that the new (P1) aggregates reconstituted from the original (P0) aggregates failed to maintain NPC. However, based on the similarity between P1 aggregates and aggregates derived from E15.5 embryonic kidneys, we suspected that the differentiated NPC in P1 aggregates may interfere with NPC maintenance. In support of this notion, we found that preventing NPC differentiation by DAPT, a γ-secretase inhibitor that inhibits Notch signaling pathway, was effective to maintain and expand Six2(+)-NPC in P1 aggregates by up to 65-fold. The Six2(+)-NPC in P1 aggregates retained their potential to epithelialize upon exposure to Wnt signal. In conclusion, we demonstrated in our present study that the "re-aggregation" system can be useful for in vitro maintenance of NPC when combined with γ-secretase inhibitor.

Indexed as

Cell Culture TechniquesAmyloid Precursor Protein SecretasesAnimalsCell Self RenewalEnzyme InhibitorsForkhead Transcription FactorsHomeodomain ProteinsMiceMice, TransgenicNephronsStem CellsTranscription FactorsAmyloid Precursor Protein SecretasesEnzyme InhibitorsForkhead Transcription FactorsFoxd1 protein, mouseHomeodomain ProteinsHoxb7 protein, mouseSix2 protein, mouseTranscription Factors

Identifiers

PMID26075891
PMCPMC4468097
OpenAlexW574521284

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.